Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

17.9K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.9K
Antibody Actions01:26

Antibody Actions

3.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.1K
Antibody Structure01:10

Antibody Structure

65.9K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.9K
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

298
Body:Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
298

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An update on patent issues regarding antibody-drug conjugates.

Nature biotechnology·2026
Same author

The CRISPR Cas patent files, part 4: All back to zero, think again!

Journal of biotechnology·2025
Same author

The CRISPR Cas patent files, part 3: Prime Editing and integrase-based variants.

Journal of biotechnology·2025
Same author

Redefining antibody patent protection using paratope mapping and CDR-scanning.

Nature biotechnology·2025
Same author

The rebirth of epitope-based patent claims.

Human antibodies·2024
Same author

The CRISPR Cas patent files, part 2: Is Cpf1/Cas12a a less conflict- prone alternative to Cas9?

Journal of biotechnology·2024

Related Experiment Video

Updated: Feb 22, 2026

IP-FCM: Immunoprecipitation Detected by Flow Cytometry
12:17

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

Published on: December 2, 2010

18.0K

The complex patent situation regarding antibody Fc engineering.

Ulrich Storz1

  • 1Michalski Hüttermann & Partner Patentanwälte mbB, Düsseldorf, Germany.

Journal of Biotechnology
|February 20, 2026
PubMed
Summary

Fc domain engineering optimizes antibody functions but faces complex patents. This guide navigates intellectual property challenges and offers strategies for antibody research and development.

Keywords:
FTOFc _engineeringPatents

More Related Videos

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Related Experiment Videos

Last Updated: Feb 22, 2026

IP-FCM: Immunoprecipitation Detected by Flow Cytometry
12:17

IP-FCM: Immunoprecipitation Detected by Flow Cytometry

Published on: December 2, 2010

18.0K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

7.4K
A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.3K

Area of Science:

  • Biochemistry and Molecular Biology
  • Immunology
  • Intellectual Property Law

Background:

  • Fc domain engineering is crucial for tailoring antibody effector functions, pharmacokinetics, and conjugation strategies.
  • The patent landscape for Fc engineering is intricate, marked by inconsistent nomenclature, overlapping claims, and evolving patent terms.

Purpose of the Study:

  • To outline key Fc engineering technologies and their associated intellectual property considerations.
  • To provide practical guidance for navigating the complex patent landscape in antibody research and development.
  • To discuss strategies for freedom-to-operate assessments and regulatory implications.

Main Methods:

  • Review of technological strategies in Fc engineering, including Fcγ receptor and FcRn affinity modulation.
  • Analysis of common intellectual property pitfalls using representative patent examples.
  • Discussion of practical approaches for freedom-to-operate, licensing, and patent protection.

Main Results:

  • Identification of key Fc engineering techniques and their patenting challenges.
  • Illustration of common intellectual property pitfalls and their impact on antibody R&D.
  • Presentation of strategies for navigating patent issues, including licensing and regulatory safe harbours.

Conclusions:

  • Effective Fc domain engineering requires careful consideration of the complex patent landscape.
  • Strategic approaches to intellectual property and freedom-to-operate are essential for successful antibody development.
  • Understanding regulatory provisions is key to mitigating risks in antibody R&D involving Fc engineering.